MEDDIC: Six Things a Deal Has to Prove Before You Forecast It

MEDDIC: Six Things a Deal Has to Prove Before You Forecast It

MEDDIC is a B2B sales qualification framework built from six checks that a deal must satisfy before a seller treats it as real: Metrics, Economic buyer, Decision criteria, Decision process, Identify pain, and Champion. It is used mainly in complex, high-value enterprise selling, and its purpose is forecasting accuracy rather than persuasion. A deal that cannot answer all six is not disqualified, it is simply not yet forecastable.

That last distinction is why MEDDIC survived when most acronyms did not. It does not tell a seller what to say. It tells a sales organisation which deals it is allowed to believe.

The six checks, and what evidence each one wants

Metrics. The number the buyer will improve, in their units, sourced from them. "They want to save time" is not a metric. "Their team spends eleven hours a week on manual reconciliation and the finance director has been asked to cut that by half" is. The test is whether you could write the business case yourself.

Economic buyer. The person who can release the money without asking anyone else. Not the person who agrees with you most, and frequently not the person you have been talking to. The test is a name, a title, and evidence of the discretionary limit.

Decision criteria. The stated basis on which they will choose. Technical requirements, commercial terms, security review, integration list. The test is whether you know the criteria well enough to predict how a competitor would be scored.

Decision process. The steps between here and a signature. Who reviews, in what order, on what dates, and which committees meet monthly rather than on demand. The test is an ordered list of named steps with dates against them.

Identify pain. The consequence of doing nothing. Every deal competes with inaction, and inaction usually wins, so a deal without a cost of delay tends to slip indefinitely regardless of how much everyone liked the demo.

Champion. Someone inside the account with influence who sells on your behalf when you are not in the room, and who has something to gain from the purchase succeeding. The test is not warmth. It is whether they have ever taken a risk for you.

The evidence each letter actually asks for

• ~Depends: Metrics: a number the buyer gave you, in their units
• ~Depends: Economic buyer: a name, and evidence they can release the budget alone
• ~Depends: Decision criteria: enough detail to predict a rival's score
• ~Depends: Decision process: named steps with dates, not a vague timeline
• ~Depends: Identify pain: what it costs them to do nothing this quarter
• ~Depends: Champion: someone who has taken a visible risk on your behalf

How it is actually used

MEDDIC is a scoring layer over an existing pipeline rather than a replacement for one. Each opportunity carries a record of what is known against each letter, usually with gaps marked explicitly, and the gaps drive the next conversation.

Two organisational habits make it work. The first is that a deal cannot advance a stage in the sales pipeline while a letter is blank, which converts an optimistic pipeline into an evidenced one. The second is that the missing letters, rather than the deal value, set the agenda for a pipeline review. A manager asking "who is the economic buyer" gets a more useful answer than one asking "will it close this month".

The framework earns its keep at deals where several people must agree, where procurement has a formal process, and where the cost of forecasting wrong is high. Below roughly the mid five figures in annual contract value it is usually heavier than the deal justifies, and the split by deal size is set out in outbound lead generation for B2B SaaS.

Where the textbook definition breaks

MEDDIC does not qualify a lead. It qualifies a deal. This is the most common misapplication and it wastes real time. The six checks require a live conversation with an engaged buyer, so they cannot be answered about a stranger, and attempting to score a fresh inbound enquiry against them produces six blanks and no information. The instrument for that stage is lead qualification, and the frameworks are not interchangeable.

Champion is the letter most often filled in falsely. A friendly contact who returns your emails feels like a champion and usually is not. The reliable signal is behavioural: they have introduced you internally, forwarded something with their own words on it, or told you about an obstacle you would not otherwise have heard about. Somebody who has never spent any internal credit on you has not yet been tested.

A complete MEDDIC record can still be a lost deal. The framework measures whether you understand the deal, not whether you are winning it. A perfectly documented opportunity where a competitor has a better relationship with the economic buyer scores well and loses. The extension that adds this explicitly is MEDDPICC, which appends checks for the paperwork route and for the competition.

It rewards writing things down, which is also how it decays. In organisations where the fields are mandatory for pipeline hygiene, they get filled with plausible text nobody has verified, and the framework becomes a reporting tax that makes the forecast look better while making it no more accurate. The check on that is spot-reading the evidence rather than the field.

MEDDICQualifies an open deal

• Requires an engaged buyer and several conversations
• Answers whether the deal is forecastable
• Owned by the seller running the opportunity
• Reviewed weekly against gaps, not against value

Lead qualificationQualifies a person before a deal exists

• Works from firmographics and a first conversation
• Answers whether this person is worth an hour
• Owned by marketing and sales development
• Reviewed as a rate across a whole cohort

Running it in a pipeline review

The framework changes behaviour only if the review changes, and most adoptions fail at that step: the fields get added to the CRM, the review carries on as a walk down the list of deals by value, and within a quarter the fields are decoration.

A review built on MEDDIC looks different in three specific ways.

It is ordered by blanks rather than by value. The largest deal with six letters filled is a well-understood opportunity that needs no discussion. The mid-sized deal with no economic buyer and no decision process is the one where a conversation might change the outcome, and it should come first.

Every filled field has to be attributable. The right question when a letter is complete is not whether the seller is confident but where the answer came from. "The champion told me the CFO signs above 50,000" is evidence. "It's usually the CFO" is a guess with a name attached, and it fails at exactly the wrong moment.

A blank is an action, not a criticism. The output of the review should be a named next step for each gap, owned by the seller, with the person they need to reach. Reviews that treat blanks as performance problems get them filled in speculatively within two weeks, which converts a diagnostic instrument into a reporting one.

The letters that go blank most often are decision process and economic buyer, and they go blank for the same reason: both require asking a question that feels presumptuous early and becomes impossible late. Sellers who ask in week two find buyers answer readily, because at that point it is a logistics question rather than a challenge. The same asymmetry applies to the paper-process check its extension adds.

One structural note. MEDDIC works best when the record is a shared artifact rather than a private one, because the value of writing down who the economic buyer is comes largely from somebody else being able to read it later. In organisations where the fields are treated as the seller's own notes, the framework survives exactly as long as the seller does.

What it means before the deal exists

The one part of MEDDIC that reaches back into outbound is identify pain, and it reaches back in reverse. You cannot know an individual stranger's pain before speaking to them, but you can know which pain is structurally likely for a company of a given shape, and a first message written from a structural guess about their situation is a different object from one written about your product.

The same is true of the economic buyer. Knowing which title actually controls the budget for your category tells you who to contact first, and it is frequently not the person whose job title matches your product name. The discovery call is where the guesses get replaced by evidence, and disqualifying well at that point is worth more than another two letters filled in optimistically.

Related terms

MEDDPICC is the extended version. BANT is the older, lighter qualification checklist that MEDDIC was a reaction against. Lead scoring is the automated cousin that operates on people rather than deals. And sales cycle is what the decision process letter is really measuring.

The short version

MEDDIC is six evidence tests applied to a live opportunity: the number they want to move, who can pay, how they will choose, what steps stand in the way, what doing nothing costs them, and who inside will argue for you. Blanks are the point. A deal with blanks is not a bad deal, it is an unfinished conversation, and a forecast that ignores the blanks is a wish. Use it to decide what to ask next, order the pipeline review by what is missing rather than by what is large, and keep the record somewhere a colleague can read it after you have gone.

Everything above assumes the conversation exists. If the constraint is getting the right person into one, that is the part we run: see what a first campaign looks like.